Journal of Psychopharmacology

 

Advanced Search

Journal Navigation

Journal Home

Subscriptions

Archive

Contact Us

Table of Contents

SAGETRACK

Click here to register today!

Sign In to gain access to subscriptions and/or personal tools.
This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to Saved Citations
Right arrow Download to citation manager
Right arrow Add to My Marked Citations
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Siris, S. G.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Siris, S. G.
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?
Journal of Psychopharmacology, Vol. 15, No. 2, 127-135 (2001)
© 2001 British Association for Psychopharmacology

Suicide and schizophrenia

Samuel G. Siris

Department of Psychiatry, Hillside Hospital Division of the North Shore, Long Island Jewish Health System and The Albert Einstein College of Medicine

Suicide and suicide attempts occur at a significantly greater rate in schizophrenia than in the general population. Common estimates are that 10% of people with schizophrenia will eventually have a completed suicide, and that attempts are made at two to five times that rate. Demographically associated with suicidality in schizophrenia are being young, being early in the course of the illness, being male, coming from a high socioeconomic family background, having high intelligence, having high expectations, not being married, lacking social supports, having awareness of symptoms, and being recently discharged from the hospital. Also associated are reduced self-esteem, stigma, recent loss or stress, hopelessness, isolation, treatment non-compliance and substance abuse. Clinically, the most common correlates of suicidality in schizophrenia are depressive symptoms and the depressive syndrome, although severe psychotic and panic-like symptoms may contribute as well. This review specifically explores the issue of depression in schizophrenia, in relation to suicide, by organizing the differential diagnosis of this state and highlighting their potentially treatable or correctable causes. This differential diagnosis includes both acute and chronic disappointment reactions, the prodrome of an acute psychotic episode, neuroleptic induced akinesia and akathisia, the possibility of direct neuroleptic-induced depression, negative symptoms of schizophrenia, and the possible co-occurrence of an independent depressive diathesis. The potential beneficial roles of 'atypical' antipsychotic agents, including both clozapine and more novel agents, and adjunctive treatment with other psychopharmacological medications are considered, and the important roles of psychosocial factors and interventions are recognized.

Key Words: assessment; depression; medication; prediction; psychopharmacology; schizophrenia; suicide; treatment


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
The Annals of PharmacotherapyHome page
P. F. Schulte
Risk of Clozapine-Associated Agranulocytosis and Mandatory White Blood Cell Monitoring
Ann. Pharmacother., April 1, 2006; 40(4): 683 - 688.
[Abstract] [Full Text] [PDF]


Home page
J PsychopharmacolHome page
C. Griffiths and R. J. Flanagan
Fatal poisoning with antipsychotic drugs, England and Wales 1993-2002
J Psychopharmacol, November 1, 2005; 19(6): 667 - 674.
[Abstract] [PDF]


Home page
Br. J. PsychiatryHome page
K. HAWTON, L. SUTTON, C. HAW, J. SINCLAIR, and J. J. DEEKS
Schizophrenia and suicide: systematic review of risk factors
The British Journal of Psychiatry, July 1, 2005; 187(1): 9 - 20.
[Abstract] [Full Text] [PDF]


Home page
Am. J. PsychiatryHome page
M. Bourgeois, J. Swendsen, F. Young, X. Amador, S. Pini, G. B. Cassano, J.-P. Lindenmayer, C. Hsu, L. Alphs, H. Y. Meltzer, et al.
Awareness of Disorder and Suicide Risk in the Treatment of Schizophrenia: Results of the International Suicide Prevention Trial
Am J Psychiatry, August 1, 2004; 161(8): 1494 - 1496.
[Abstract] [Full Text] [PDF]


Home page
NEJMHome page
R. Freedman
Schizophrenia
N. Engl. J. Med., October 30, 2003; 349(18): 1738 - 1749.
[Full Text] [PDF]


Home page
Arch Gen PsychiatryHome page
H. Y. Meltzer, L. Alphs, A. I. Green, A. C. Altamura, R. Anand, A. Bertoldi, M. Bourgeois, G. Chouinard, M. Z. Islam, J. Kane, et al.
Clozapine Treatment for Suicidality in Schizophrenia: International Suicide Prevention Trial (InterSePT)
Arch Gen Psychiatry, January 1, 2003; 60(1): 82 - 91.
[Abstract] [Full Text] [PDF]